Pilot human study to define the impact of vascular and inflammatory risk factors in Alzheimers disease

PRESTIA, FEDERICO ARIEL; CASTAÑO, EDUARDO MIGUEL; BRUSCO, LUIS IGNACIO; GALEANO, PABLO; POLITIS, DANIEL GUSTAVO; MORELLI, LAURA; DALMASSO, MARÍA CAROLINA; KOCHEN, SILVIA

Montreal

Congreso; ISN ASN 2019 Meeting; 2019

International Society for Neurochemistry

Clinical evidence suggests a leading role of vascular and inflammatory risk factors in Alzheimer disease (AD). Angiogenic factors, chemokines and proinflammatory cytokines were evaluated in plasma of control (CTR, n=20) and sporadic AD (n=18) patients recruited from hospitals in Argentina. Statistical comparisons were carried out by Student or Mann Whitney tests. Moreover, cognitive performance was evaluated with the MMSE test and, as expected, significant differences were observed between groups. Levels (pg/mL) of 41 analytes were determined by multiplex ELISA (V PLEX Human Biomarker kit MSD Technology). From the 41 analytes, 33 were detected in most of the patients and significant differences were observed in the levels of 16 of them (GMCSF; IL16; VEGF; IL8; TNFalpha; EOTAXIN; EOTAXIN3; IP10; MDC; MIP1alpha; MIP1beta; sVCAM1; Fit1; PIGF; VEGFA). It is of note that IL1beta was only detected in AD patients. A discriminant analysis performed with all of the data revealed that 81.6% of subjects (AD: 83.3%; CTR: 80%) were correctly classified. To determine whether APOe4, the most relevant genetic risk factor for AD, was associated with particular analytes, AD patients were divided into two groups: APOe4(+) and APOe4(-). GMCSF was the only analyte that was significantly different between groups (0.068+/-0.006 vs. 0.030+/-0.007). These results suggest that a set of circulating vascular and inflammatory factors is able to discriminate between AD and CTR patients, while further studies are required to determine the relationship between genetic risk factors and plasma biomarkers.